ODI PHARMA AB Cash Flow Conversion Efficiency
ODI PHARMA AB cash flow conversion efficiency. Based on the latest financial reports, ODI PHARMA AB (6OD) has a cash flow conversion efficiency ratio of 0.153x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€364.19K ≈ $425.78K USD) by net assets (€2.38 Million ≈ $2.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ODI PHARMA AB (2022–2026)
Cash flow conversion efficiency of ODI PHARMA AB from 2022 to 2026. This chart illustrates how ODI PHARMA AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ODI PHARMA AB share price for real-time trading data and today's change.
ODI PHARMA AB Cash Flow Conversion Ratio Explained
ODI PHARMA AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ODI PHARMA AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ODI PHARMA AB ranked by their cash flow conversion efficiency. Also see 6OD market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Casa Minerals Inc
V:CASA
|
0.040x |
|
Damon Inc. Common Stock
NASDAQ:DMN
|
0.392x |
|
Opthea Limited
NASDAQ:OPTEY
|
N/A |
|
Elixirr International Plc
LSE:ELIX
|
0.160x |
|
ROLLING OPTICS HOLDING AB
F:5LN
|
-0.033x |
|
Preecha Group Public Company Limited
BK:PRECHA
|
-0.044x |
|
Marquee Resources Ltd
AU:MQR
|
-0.085x |
|
BIO-Key International Inc
NASDAQ:BKYI
|
-0.238x |
Annual Cash Flow Conversion Efficiency for ODI PHARMA AB (2022–2026)
The table below shows the annual cash flow conversion efficiency of ODI PHARMA AB from 2022 to 2026. Review 6OD free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | €2.38 Million ≈ $2.78 Million |
€4.58 Million ≈ $5.35 Million |
1.926x | +124.75% |
| 2025-06-30 | €424.64K ≈ $496.45K |
€-3.31 Million ≈ $-3.86 Million |
-7.785x | -307.41% |
| 2024-06-30 | €2.00 Million ≈ $2.34 Million |
€-3.82 Million ≈ $-4.47 Million |
-1.911x | +3.68% |
| 2023-06-30 | €2.57 Million ≈ $3.01 Million |
€-5.10 Million ≈ $-5.97 Million |
-1.984x | -149.15% |
| 2022-06-30 | €9.26 Million ≈ $10.83 Million |
€-7.37 Million ≈ $-8.62 Million |
-0.796x | -- |
About ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products. ODI Pharma AB (publ) was founded in 2018 and is based in Stockholm, Sweden.